Authors
Latest:
Dr Phillips on the Use of Bispecific Antibodies and CAR T-Cell Therapy in MCL and FLTycel Phillips, MD, MPH, discusses the use of bispecific antibodies and CAR T-cell therapy across hematologic malignancies, including in patients with mantle cell lymphoma and follicular lymphoma.
Latest:
Key Takeaways From DiscussionPhysicians share key takeaways from the discussion on diagnosis and treatment of immune thrombocytopenia.
Latest:
ACCC Welcomes Matt Devino, MPH, as Director, Cancer Care Delivery and Health PolicyThe Association of Community Cancer Centers announced that Matt Devino, MPH has joined the organization as Director, Cancer Care Delivery and Health Policy.
Latest:
Unmet Needs and Future Perspectives in the NSCLC Treatment LandscapeLooking to the future, a panel of experts offer closing remarks on promising developments and unmet needs in the treatment of NSCLC.
Latest:
Future Directions in Precision Medicine: An Evolving Treatment LandscapeClosing out their discussion on biomarkers and precision medicine in cancer care, key opinion leaders look toward future evolutions in the oncology landscape.
Latest:
Dr Sun on Ongoing Research Efforts Examining Clonal Hematopoiesis in RCCMaxine Sun, PhD, MPH, discusses ongoing research efforts dedicated to examining the relationship between clonal hematopoiesis and cardiovascular disease in patients with renal cell carcinoma.
Latest:
Smoking Cessation Support Plays a Vital Role in Improving Lung Cancer ScreeningResults of the National Lung Screening Trial demonstrated a 20% decrease in lung cancer mortality in individuals aged 55 to 74 years with a 30 pack-year smoking history using a low-dose computed tomography scan.
Latest:
CAR T-Cell Therapy for Multiple Myeloma: Eliminating Disparities Through AccountabilityAlthough the first FDA approval for CAR T-cell therapy in multiple myeloma was 2 years ago, unfortunately, the treatment remains out of reach for too many patients.
Latest:
Dr. Gulhati on Current Treatment Approaches in Pancreatic CancerPrateek Gulhati, MD, PhD, discusses current treatment approaches in pancreatic cancer and strategies under investigation within the space.
Latest:
Trastuzumab/Pertuzumab May Be an Effective Chemo-Free Regimen in HR+/HER2+ Breast CancerDual HER2 blockade with trastuzumab plus pertuzumab may serve as an effective option for hormone receptor–positive, HER2-positive metastatic breast cancer.
Latest:
Dr Basho on Treatment Considerations With ADCs in Breast CancerReva K Basho, MD, discusses the use of antibody-drug conjugates across the spectrum of breast cancer subtypes at the 2023 Bridging the Gaps in Breast Cancer meeting.
Latest:
Key Takeaways on Evolving Bladder Cancer Treatment LandscapeThe expert panel concludes its discussion by providing key takeaways on the evolving bladder cancer treatment landscape following ESMO 2023.
Latest:
Metastatic Colorectal Cancer: Ongoing Challenges and Future Directions in CareClosing out their panel on metastatic colorectal cancer, expert oncologists consider ongoing challenges and future evolutions within the treatment landscape.
Latest:
Dr Elder on the Initial Safety Profile of IGV-001 in Newly Diagnosed GlioblastomaJ. Bradley Elder, MD, discusses blinded early-safety data from a phase 2b trial of IGV-001 in patients with newly diagnosed glioblastoma.
Latest:
Dr Serzan on the Rationale for Evaluating Botensilimab Plus Balstilimab in Advanced RCCMichael Serzan, MD, discusses the rationale for evaluating botensilimab/balstilimab for patients with advanced renal cell carcinoma.
Latest:
Mentoring Oncologists in the Era of Social DistancingMentoring is critically important to the development of young academic hematology/oncology trainees.
Latest:
Dr Tsuboi on Updated Survival Results of the ADAURA Trial in Resectable NSCLCMasahiro Tsuboi, MD, discusses the updated survival results of the phase 3 ADAURA trial in resectable EGFR-mutant non–small cell lung cancer.
Latest:
Novel Treatment Combinations in Chronic Lymphocytic LeukemiaDr Brown and Dr Stilgenbauer provide their input on novel treatment options emerging for chronic lymphocytic leukemia.
Latest:
Dr Vincelette on MYC Expression in MyelofibrosisNicole D. Vincelette, PhD, discusses the role of MYC expression in a subgroup of triple-negative myeloproliferative neoplasms.
Latest:
Dr Narayan on Variations in Breast Cancer Outcomes by RaceAnand Narayan, MD, PhD, discusses how outcomes differ between different subgroups of patients who are diagnosed with breast cancer, highlighting how these differences tie back to disparities in cancer care.
Latest:
Dr. George on Actionable Pathogenic Variants in Adults With Breast or Ovarian Cancers in the CaribbeanSophia George, PhD, discusses actionable pathogenic variants in patients with breast cancer who live in the Caribbean.
Latest:
A Phase 1 Clinical Trial Evaluating Monotherapy With Exarafenib (KIN-2787), a Highly Selective Pan-RAF Inhibitor, in BRAF‑Altered Solid Tumors and NRAS-Mutant MelanomaAlexander I. Spira, MD, PhD, shares new dose escalation data from the first-in-human Phase 1 KIN-2787 study of the pan-RAF inhibitor exarafenib in patients with BRAF-altered solid tumors or NRAS-mutant melanoma.
Latest:
Expanding the Patient Pool for ImmunotherapiesAlthough immune checkpoint inhibitors can yield dramatic results and give some patients many years of life, some patients do not yield benefit.
Latest:
Narsoplimab Trial ResultsThe panel of transplant experts discuss the results of the phase 2 trial of narsoplimab and the pending FDA approval of this agent for treatment of transplant-associated of thrombotic microangiopathy.
Latest:
Dr. Rapisuwon on Clinical Trial Barriers in the United States in Mucosal MelanomaSuthee Rapisuwon, MD, discusses clinical trial barriers for patients with mucosal melanoma in the United States.
Latest:
Dr Yentz on Treatment Decisions in Favorable-Risk RCCSarah Elizabeth Yentz, MD, discusses treatment considerations in patients with favorable-risk renal cell carcinoma.
Latest:
The Evolving Treatment Landscape in SCLCBeth Sandy, MSN, CRNP, discusses the evolving treatment landscape in small cell lung cancer.
Latest:
Investigators Seek to Resolve the “Obesity Paradox” in Lung CancerSmoking is associated with the most widely known cancer causing carcinogen across the world. However, a second, more insidious factor has been increasingly recognized for its role in promoting cancer growth: obesity.
Latest:
Dr Ramalingam on Updates in Lung Cancer Following the 2024 ASCO Annual MeetingSuresh S. Ramalingam, MD, FACP, FASCO, and Chandler H. Park, MD, FACP, discuss updates in non–small cell lung cancer at the 2024 ASCO Annual Meeting.
